OPEN END TURBO OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 05:58:17 08/07/2024 pm IST | ||
| 6.26 EUR / 6.56 EUR | +1.10% |
|
| Current month | -4.37% | ||
| 1 month | +17.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 08/24/08 | 6.16 | -2.84% |
| 05/24/05 | 6.34 | -3.50% |
| 04/24/04 | 6.57 | -1.05% |
| 03/24/03 | 6.64 | +5.23% |
| 02/24/02 | 6.31 | -3.66% |
Delayed Quote Börse Stuttgart
Last update July 08, 2024 at 02:47 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB4FZD |
| ISIN | DE000JB4FZD9 |
| Date issued | 16/10/2023 |
| Strike | 541.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 16.57 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.26 € |
|---|---|
| Lowest since issue | 5.19 € |
| Spread | 0.3 € |
| Spread % | 4.55% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Certificates
- Certificat
